Shinva Medical Instrument Co. Ltd. Class A

Shinva Medical Instrument Co. Ltd. Class A

SSSE:600587
12.27
CNY
-0.06
(-0.49%)
0.73EPS
17.52P/E
7.90BMarket Cap
Apr 23Next Earn
Shinva Medical Instrument Co. Ltd. Class A
SSE:600587
(Shanghai Stock Exchange)

Recent

price

12.27

P/E

ratio

17.52

div

yld

3.16%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.85
5.44
7.01
8.91
12.14
14.28
16.72
18.75
20.83
16.6
17.44
17.96
17.56
16.84
16.52
16.09
16.6
Revenue per Share
0.17
0.28
0.38
0.49
0.63
0.53
0.07
0.12
0.05
1.63
0.45
1.05
0.95
1.1
1.14
0.87
0.74
Basic EPS, GAAP
0.05
-0.36
-0.4
-1.07
-0.92
-1.05
-0.99
0.79
-0.15
0.79
1.73
2.14
0.27
0.83
0.05
0.53
- -
Free Cash Flow per Basic Share
0.03
0.13
0.13
0.11
0.22
0.31
0.37
0.43
0.44
0.38
0.29
0.24
0.18
0.17
0.54
0.57
0.39
Dividend per Share
1.79
2.03
3.27
4.67
5.56
6.13
6.15
6.24
6.26
7.91
8.3
9.3
10.07
12.06
12.52
12.58
13.09
Book Value per Share
1.67
1.82
2.36
3.12
2.88
3.28
3.35
3.85
4.12
6.32
6.8
7.92
8.67
10.85
11.35
11.45
11.98
Tangible Book Value per Share
349
387
433
471
518
529
500
532
494
528
525
528
529
595
607
605
609
Basic Weighted Avg Shares
1,342
2,106
3,036
4,194
6,283
7,554
8,364
9,983
10,284
8,767
9,151
9,482
9,282
10,012
10,021
9,736
10,113
Sales/Revenue/Turnover
6.06
7.15
7.83
8.32
9.14
7.62
5.52
5.95
6.13
3.85
6.77
7.08
7.47
8.07
8.99
7.23
7.22
Operating Margin (%)
17
19
28
40
64
106
133
153
186
187
179
201
197
213
210
233
- -
Depreciation Expense
60
107
163
232
326
281
35
66
23
861
234
556
500
654
692
526
453
Net Income, GAAP
17.03
18.25
17.65
19.27
21.33
24.15
40.74
47.31
49.73
23.25
30.67
22.56
8.54
8.41
13.04
10.66
13.02
Effective Tax Rate (%)
4.5
5.09
5.38
5.52
5.2
3.72
0.41
0.66
0.22
9.82
2.56
5.87
5.39
6.53
6.9
5.41
4.48
Profit Margin (%)
421
408
714
831
750
374
-535
-711
-884
-499
-250
156
479
1,957
2,129
2,346
2,823
Working Capital
6
6
6
5
296
279
272
523
444
465
525
148
125
175
108
139
193
LT Debt
777
871
1,625
2,723
3,454
3,967
4,018
4,125
4,162
4,693
4,858
5,268
5,787
7,720
7,983
7,957
8,257
Total Equity
8.19
11.39
10.55
8.32
7.84
4.65
0.87
1.82
1.52
11
3.48
8.38
8.24
9.1
8.06
6.03
4.68
Return on Invested Capital (%)
7.38
10.45
9.7
7.92
7.19
4.79
0.64
1.04
0.23
12.49
4.21
9
7.82
8.55
8.15
6.15
5.29
Return on Capital (%)
8.96
14.44
14.41
11.91
12.26
9.13
1.07
2
0.69
23.02
5.47
11.97
9.7
10.29
9.27
6.91
5.73
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
978
899
888
LT Borrowings
124
131
150
LT Finance Leases
59
47
42
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
607
607
607
Market Capitalization
8,657
7,207
7,899

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
8,819
9,108
9,073
Cash, Cash Equivalents & STI
3,111
3,104
3,015
Accounts Receivable, Net
1,971
2,317
2,223
Inventories
2,791
2,644
2,718
Total Current Liabilities
6,245
6,396
6,250
Payables & Accruals
- -
- -
- -
ST Debt
978
899
888
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.59%
10.95%
-0.32%
Free Cash Flow
20.13%
212.76%
969%
Net Income, GAAP
368.4%
28.03%
-23.9%
Sales/Revenue/Turnover
2.93%
1.33%
-2.84%
Total Cash Common Dividend
18.95%
37.5%
4.13%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,529
2,658
2,237
2,597
10,021
2025
2,308
2,483
- -
2,758
9,736
2026
2,254
2,907
2,195
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.46
0.22
0.12
1.14
2025
0.27
0.37
- -
0.15
0.87
2026
0.2
0.27
0.12
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.29
0.15
0.01
0.54
2025
0.03
0.01
- -
0.25
0.57
2026
0.01
0.11
0.01
- -
- -
Business
Shinva Medical Instrument Co., Ltd. (600587.SS) manufactures and markets medical devices, pharmaceutical equipment, and related healthcare solutions primarily in China with exports to over 110 countries and regions. Founded in 1943 and headquartered in Zibo, Shandong Province, the company offers infection control products including steam sterilizers such as the Tianxuan series, rapid formaldehyde sterilizers like the Qiming series, vacuum washer-disinfectors such as the Bengten series, and flexible endoscope washer-disinfectors like the Hanghai series; radiotherapy equipment featuring intelligent online adaptive systems with ring gantry structures; surgical instruments and orthopaedics tools encompassing standard, neuro, cardiovascular, laparoscopic, and orthopedic variants; operating room solutions including the STable-M8000 electric operating table driven by 16 DC motors and the SFace-pipe anesthesia circuit disinfector; dental equipment and consumables; in-vitro diagnostic reagents and instruments; biological materials and consumables; dialysis equipment such as hemodialysis products; and medical environmental protection systems like waste treatment and air purifiers. It also provides pharmaceutical machinery for large and small volume injections, freeze dryers, and aseptic systems; turnkey integrated solutions for CSSD, radiotherapy, digital operating rooms, infection control, pharmaceuticals, dental care, and experimental animal safeguards; and medical services with five overseas sales centers in Russia, Germany, Indonesia, Vietnam, and Egypt. In recent developments, Shinva showcased innovations at the 91st CMEF in April 2025 and MEDICA 2025, highlighting smart healthcare solutions including the Qiming sterilizer validated for Da Vinci instruments and the SMors surgical behavior management system; received medical device registration certificates in 2025 for products such as steam sterilizers, X-ray CT equipment, disposable hemodialysis tubing, surgical sutures, and cleaning/disinfecting devices; announced in December 2024 the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology Co., Ltd. for RMB 166.5 million to expand into respiratory testing and enrich its product pipeline; reported first-half 2024 revenue of RMB 5.187 billion (up 2.24% year-over-year) and net profit of RMB 484 million (up 5.57%), with nine-month 2024 net profit of RMB 617 million (up 6.63%); and invested heavily in R&D, securing 85 new patents in 2025 (up 41.72% year-over-year) while committing to carbon neutrality by 2060.